IDiyas

For the Inventor, By the Inventor

Welwyn, United Kingdom

Cedric H Hassall

USPTO Granted Patents = 36

Average Co-Inventor Count = 3.6

ph-index = 12

Forward Citations = 451(Granted Patents)


Location History:

  • Welwyn, EN (1977 - 1978)
  • Hatfield, GB (1981 - 1982)
  • Welwyn, GB (1978 - 1985)
  • Harpenden, GB (1983 - 1989)

Company Filing History:

goldMedal36 out of 4,942 
 
Hoffmann-la Roche Inc.
 patents

Years Active: 1977-1989

Loading Chart...
36 patents (USPTO):Explore Patents
1. 4826980 - Pyridazine intermediates (1989-05-02),
2. 4808713 - Anthypertensive pyridazo [1,2-a][1,2]diazepines (1989-02-28),
3. 4785093 - Bicyclic compounds (1988-11-15),
4. 4772701 - Pyridazo[1,2]pyridazines and pyrazolo[1,2]pyridazines as (1988-09-20),
5. 4762924 - Bicyclic compounds (1988-08-09),
6. 4692438 - Pyridazo-diazepines, diazocines, and -triazepines having (1987-09-08),
7. 4658024 - Pyrazolo [1,2-a][1,2]-diazepines useful as antihypertensives (1987-04-14),
8. 4623639 - Peptide derivatives (1986-11-18),
9. 4591636 - Anthracycline glycosides (1986-05-27),
10. 4526960 - Anthracycline glycosides (1985-07-02),
11. 4518784 - Cyclic compounds (1985-05-21),
12. 4515969 - Cyclic compounds (1985-05-07),
13. 4512924 - Pyridazo[1,2-a][1,2]diazepines (1985-04-23),
14. 4487929 - Intermediates for pyrazolopyridazine derivatives (1984-12-11),
15. 4409391 - Process to produce anthracycline compounds (1983-10-11),

Title: Innovations in Antihypertensive Compounds by Cedric H. Hassall

Introduction

Cedric H. Hassall, an accomplished inventor based in Welwyn, Great Britain, has made significant contributions to the field of pharmacology with an impressive portfolio of 36 patents. His work primarily focuses on the development of novel compounds with antihypertensive activity, which have potential applications as medicaments.

Latest Patents

Among Cedric H. Hassall's latest patents are groundbreaking innovations related to pyridazine intermediates and antihypertensive pyridazo [1,2-a][1,2]diazepines. One notable patent describes compounds with the formula that includes various structural components, which exhibit antihypertensive activity and can be used as pharmaceutical preparations. These compounds feature multiple asymmetric carbon atoms, allowing for the creation of different optically uniform forms as well as isomeric mixtures. Another patent focuses on new compounds that demonstrate antihypertensive properties and can be combined with various functional groups to enhance their therapeutic efficacy.

Career Highlights

Cedric H. Hassall's career is marked by his affiliation with Hoffmann-La Roche Inc., a leading global health company. His expertise in the pharmaceutical field has led to the development of innovative compounds that address critical health issues. His commitment to research and development has solidified his reputation as a key player in the pharmaceutical sector.

Collaborations

Throughout his career, Cedric has collaborated with esteemed colleagues, including Robert W. Lambert and Geoffrey Lawton. These partnerships have fostered an environment of innovation and creativity, driving forward advancements in pharmaceutical chemistry and hypertension treatment options.

Conclusion

In summary, Cedric H. Hassall stands out as a prominent inventor whose work has significantly impacted the development of antihypertensive medications. With 36 patents to his name, his contributions continue to pave the way for new therapeutic approaches to managing hypertension, showcasing the importance of innovation in medicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…